MedTechnology

Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central

23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…

ByByAnuja Singh Jan 24, 2026

Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?

23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…

ByByAnuja Singh Jan 24, 2026

Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate

23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…

ByByAnuja Singh Jan 24, 2026

Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66 Million NLRP3 Licensing Deal

23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…

ByByAnuja Singh Jan 24, 2026
Image Not Found

Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge

Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…

ByByAnuja Singh Mar 2, 2026

Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?

Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…

ByByAnuja Singh Mar 1, 2026
Scroll to Top